Both FDA and Congress are taking interest in combating antibiotic resistance, but FDA likely has more power to make headway in the near term, even as industry remains somewhat wary of that particular agenda item.

M&A can be expensive, but sometimes deals pay huge dividends. Bristol’s $2.1 billion acquisition of Medarex from 2009 looks like it’ll pay for itself many times over. Plus Actavis buys Warner Chilcott, Novo buys Xellia, and Elan and BTG each keep very busy.

Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.